| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Department of Physiology and Biophysics, University of Miami School of Medicine, Miami, Florida 33101; 2Department of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; 3Department of Pediatrics, State University of New York, Stony Brook 11794; and 4Departments of Medicine and Pharmacology, New York Medical College, Valhalla, New York 10595
Submitted 28 May 2003 ; accepted in final form 10 September 2003
 |
ABSTRACT |
|---|
 TOP ABSTRACT MATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-activated HUVEC layer were twice as high as those of the HUVEC bodies. HL-60 adhesion to the monolayer was significantly reduced by a monoclonal antibody against 
1-integrins and partially inhibited by antibodies against selectins ICAM-1 and VCAM-1 but was not affected by anti-V3. Interestingly, adhesion was also inhibited in a dose-dependent manner (IC50 
100 nM) by a cyclic arginine-glycine-aspartic acid (cRGD) peptide. This effect was mediated via interfering with the VLA-4-VCAM-1 binding. In parallel measurements, transmigration of HL-60 cells across a confluent HUVEC monolayer was inhibited by the cRGD peptide and by both anti-1 and anti-V3 antibodies. In conclusion, these data demonstrate the role played by 1-integrins in leukocyte-endothelial adhesion and transmigration and the role played by V3 in transmigration, thus underscoring the high efficacy of cRGD peptide in blocking both the adhesion and transmigration of monocytes.
integrins; cell-cell adhesion; arginine-glycine-aspartic acid peptide
1-, 2-, 7-integrins; PECAM-1 on leukocytes and P- and E-selectins; ICAM-1 and ICAM-2; VCAM-1, MadCAM-1, and PECAM-1; and 1-integrins on endothelial cells (6). Therapeutic strategies based on inhibiting some of these interactions with neutralizing antibodies have been successfully applied to the animal models of ischemia-reperfusion and acute inflammatory processes (16, 29). To study the intimate molecular mechanisms of leukocyte-endothelial interaction, a quantitative evaluation of cell adhesion is necessary. The commonly used methods for the evaluation of leukocyte adhesion are various forms of cell adhesion assays, which quantify adhesion by counting the number of bound cells. Although these assays provide a convenient means to estimate adhesion, they do not reveal the underlying biophysical mechanisms of cell-cell interaction. The main reason is due to the fact that in these methods, the bound cell numbers are counted a posteriori. Therefore, the detailed information on the dynamics of cell-cell interaction is missing.
In this work, we have employed the atomic force microscopy (AFM) (4) to quantify whole cell adhesion. A single live leukocyte, attached to end of the AFM cantilever, served as a functionalized probe that monitored leukocyte-endothelial interaction in real time. Taking advantage of the high temporal, spatial, and force resolutions of this technique, we have measured the adhesive interaction of the leukocyte over different locations in the endothelial monolayer and evaluated the relative contribution of different adhesion molecules in supporting cell adhesion. The inhibitory potency of different function-blocking antibodies and a cyclic arginine-glycine-aspartic acid (cRGD) peptide was also further investigated.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
(TNF-, 100 ng/ml) for 6 h at 37°C. HUVECs were used between passages 5 and 7.
Proteins and other reagents. Human TNF-, human recombinant P-selectin-Fc, and VCAM-1-Fc fusion proteins were purchased from R&D Systems (Minneapolis, MN). cRGD and cyclic Arg-Ala-Asp-D-Phe-Val (cRAD) were purchased from Bachem (King of Prussia, PA), and CellTracker CM-Dil (C-7000) was purchased from Molecular Probes (Eugene, OR). Human function-blocking antibodies BBIG-E4 (anti-E-selectin), BBIG-I1 (anti-ICAM-1), and AF809 (anti-VCAM-1) were purchased from R&D Systems. LM-609 (anti-V3) and JB1A (anti-1) were from Chemicon International (Temecula, CA). WAPS-12.2 (anti-P-selectin) was purified from culture supernatant of WAPS-12.2 hybridomas (ATCC; Manassas, VA) by protein A column. All other reagents were from Sigma (St. Louis, MO).
Protein immobilization. VCAM-1/Fc (30 µl) and P-selectin/Fc (25 µg/ml) in 0.1 M NaHCO3 (pH 8.6) were adsorbed overnight at 4°C on the center of a 35-mm tissue culture dish (Falcon, Becton-Dickinson). Unbound proteins were removed, and bovine serum albumin (BSA, Sigma) at 100 µg/ml in PBS was used to block the exposed surface of the dish.
Measurement of leukocyte adhesion by atomic force microscopy. The AFM instrument used was as described earlier (7). Briefly, cells were localized using an inverted optical system. The position of the AFM tip was set by a piezotranslator with a strain gauge position sensor (Physik Instrumente; Waldbronn, Germany). The interaction between the AFM tip and the substrate was determined from deflection of the AFM cantilever. Cantilevers were calibrated by thermal fluctuation analysis according to the method of Hutter and Bechhoefer (12) and had a spring constant of 
0.010 Nm–1.
Individual HL-60 cells were attached to the tip of a cantilever through Concanavalin A (Con A)-mediated linkages (see Fig. 1) (2, 30). The cantilevers were first incubated in 0.5 mg/ml biotinamidocaproyl-labeled BSA overnight at 37°C and then rinsed with PBS and incubated in 0.5 mg/ml streptavidin for 10 min at room temperature. Finally, the cantilevers were incubated in 0.5 mg/ml biotinylated Con A. All AFM studies were conducted at 25°C in phenol red-free RPMI 1640 medium containing 10 mM HEPES. For cell attachment, the tip of the Con A-functionalized cantilever was positioned above the center of a cell and gently lowered onto the cell for 1 s. The HL-60 firmly adhered to the Con A on the AFM tip and was then used to probe adhesion. To measure the unbinding of the HL-60 from endothelial cells, the strength of cantilever-leukocyte linkage and the endothelial cell-substrate linkage must be much larger than the strength of the leukocyte-endothelial cell interaction. To obtain an estimate of the strength of the cell-cantilever linkage, we allowed the attached HL-60 cell to interact for 1 min with a tissue culture dish coated with Con A. On retraction of the cantilever, separation always (N > 30) occurred between the cell and the Con A-coated surface. This is likely due to the fact that the contact area formed between the cantilever and the cell is larger than that between the cell and the substrate. The average force needed to induce separation was >2.3 nN, which was at least two times larger than the detachment forces recorded in this study (<700 pN). As for the other linkage in the experimental system, i.e., the linkage between HUVEC and the petri dish, Sagvolden et al. (22) have shown that the deadhesion force between an adherent cell and the dish is at least 20 nN. In fact, we never observed the detachment of HUVEC from the petri dish during our force measurements. In the experiments using function-blocking antibodies or peptides, immobilized proteins or HUVECs were incubated with different antibodies (50 µg/ml each) or different concentrations of peptides for 30 min before the force measurements.
|
Leukocyte adhesion assay. Falcon culture plates (24-well) were coated with 0.2% gelatin overnight, sterilized under UV light for 20 min, and plated with HUVEC. Confluent HUVEC were then stimulated with TNF- (100 ng/ml) for 6 h at 37°C. HL-60 cells were loaded with CM-Dil cell tracker, washed with PBS twice, and resuspended in RPMI 1640 medium. After washing was completed, 20,000 cells in 0.7 ml medium (RPMI/Hanks) were added to each well with a confluent monolayer of TNF--stimulated HUVEC. Different concentrations of cRGD (10 nM-10 µM) or cRAD (1 µM) were tested by adding them to each well (one well was kept as control with no additions). In a separate series of experiments, monoclonal blocking antibodies (specified in RESULTS) were added to stimulated HUVEC monolayers coincubated with cell tracker-labeled monocytes. Monocyte-endothelial cell interaction was quantified after 30 min. Nonadherent monocytes were removed by gentle washing with PBS.
Leukocyte transmigration assay. Transmigration assays were performed using Boyden chemotaxis chamber (Neuro Probe; Gaithersburg, MD). RPMI (30 µl) with N-formyl-Met-Leu-Phe (10 nM) were added to each well of the lower chamber. Polycarbonate membrane with 5-µm pores was placed gently on top of the lower chamber. Membrane in each well was coated with gelatin (10 mg/ml) and allowed to dry for 2 h. HUVEC were stimulated with TNF- (100 ng/ml) for 6 h, trypsinized, and resuspended in a nonphenolated RPMI 1640 medium, and 40 µl of the suspension were added to each well of the upper chamber for 2-h incubation at 37°C and 5% CO2. Differentiated HL-60 cells (1 x 105 CM-Dil labeled) were added to each well for 4-h transmigration. To assess the integrity of HUVEC monolayers, cells on polycarbonate filters were stained with Wright-Giemsa at the completion of the transmigration assays. Transmigrated monocytes were counted under low-power magnification in 5 fields/well. Each experiment was performed in triplicate, and experiments were repeated at least three times.
Statistical analysis was performed by two-tailed t-test or ANOVA, with P < 0.05 considered statistically significant. The data were presented as means ± SE.
|
RESULTS |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
To obtain a quantitative measure of the adhesion strength on a whole cell level, we introduced two adhesive indexes: one being the detachment force and the other the work of deadhesion (Fig. 2B). Detachment force is the maximal adhesive force detected by the cantilever during cell-substrate separation. The work of deadhesion, as indicated by the shaded area in Fig. 2B, top trace, is the work done by the cantilever to separate the cell and was derived from integrating the adhesive force over the distance traveled by the cantilever up to the point of the last bond rupture. It included the work done to break the molecular linkages and the work done to stretch the cells. For the experimental conditions shown in Fig. 2B, our data revealed an average detachment force of 320 ± 30 pN and the work of deadhesion of 7.8 ± 1.3 x 10–16 J. In the presence of a function-blocking antibody against VCAM-1, both the detachment force and work of deadhesion were substantially reduced to 80 ± 8 pN (75% decrease) and 3 ± 0.8 x 10–17 J (96% decrease), respectively. Hence, both indexes seem to be specific in reflecting the adhesion between HL-60 and the substrate. More significant difference was found if adhesion is measured by the work of deadhesion. This is probably due to the fact that the work of deadhesion reflects both the difference in force and the difference in the stretching distance during cell-substrate separation. Similar results were seen on HL-60 cell adhesion to other adhesion molecules, including P-selectin, E-selectin, and ICAM-1 (data not shown).
We next tested whether AFM method is suitable for a surface presenting different types of adhesion molecules, which closely resemble activated endothelium. Dishes coated with both VCAM-1 and P-selectin were studied (Fig. 3). In these experiments, anti-VCAM-1 or anti-P-selectin alone only partially inhibited adhesion. The adhesion was completely blocked in the presence of both antibodies but was not affected by nonspecific mouse Ig (P > 0.05) (Fig. 3). Hence, these experiments indicated that the AFM method could specifically reveal the adhesion strength of the HL-60 cell interacting with different endothelial-derived adhesion molecules and should be suitable for studying leukocyte adhesion to vascular endothelial cells. In addition, these experiments proved the potency of each of function-blocking antibodies against specific adhesion molecules and validated their usage for blocking adhesion on endothelial cells.
|
AFM measurement of leukocyte-HUVEC interaction. Experiments were carried out between a HL-60 cell attached to the end of an AFM cantilever and a HUVEC monolayer plated on a tissue culture dish (Fig. 1C). The HUVEC monolayer was activated by TNF-, a well-defined in vitro model of the activated endothelium. A complete cycle of the AFM force scan is illustrated in Fig. 4A and is similar to that of Fig. 2A. Figure 4B, top trace, represents a typical force curve of the interaction between a HL-60 cell and the cell body of an activated HUVEC. The deadhesion process involved multiple rupture events before finial separation. Several well-defined rupture events are highlighted in Fig. 4B. The magnitude of these rupture events was between 40 and 100 pN, which is consistent with the reported unbinding force of selectin or integrin bonds (9, 17, 24, 30). Figure 4B, middle trace, presents a record of the interaction between HL-60 and unstimulated HUVEC, which showed significantly fewer bond-rupturing events and a lower work of deadhesion. The enhanced adhesion of HUVEC following TNF- activation has been attributed to an upregulation of adhesion molecules such as E-selectin, VCAM-1, and ICAM-1 (3, 20). A significant decrease in adhesion between HL-60 and TNF--activated HUVEC was observed in the presence of a cocktail of function-blocking antibodies against P, E-selectins, VCAM-1, and ICAM-1. (Fig. 4B, bottom trace).
|
Past single molecule studies demonstrated that the unbinding force of individual ligand-receptor bonds varies more or less with the loading rates applied to the bonds. Experimentally, the loading rate is adjusted by changing the separation speeds. To find out whether our experimental result is altered by separation speeds (loading rates), we tested three different separation speeds: 0.5, 3, and 6 µm/s (Fig. 5). As shown, varying the speed 10-fold only induced a subtle difference in adhesion (P > 0.05). This result demonstrated that in the loading regime being tested in this study, the loading rate is not a key factor that significantly affects the experimental results. In an in vivo study using intravital microscopy, Kunkel et al. (14) showed that the speed of leukocyte rolling on a TNF--activated endothelium was between 0.3 and 9 µm/s, with an average speed of 3.9 µm/s. Hence, the separation speed used in this study, i.e., 3 µm/s, is close to the physiological separation speed of leukocyte-endothelial interaction. The loading regime being tested in Fig. 5 is physiologically relevant.
|
Another factor that may affect the loading rate is the mechanics of both the HL-60s and the HUVECs. The mechanical properties of these two cell types were measured by AFM indentation experiments. The measurements were made with indentations of <1 µm on HL-60s and <300 nm on HUVECs. Estimates of Young's modulus were based on the Hertz model (27). The average value for Young's modulus (N > 100; 10–15 cells) of the HL-60s was 0.4 kPa, and the Young's modulus of the resting and activated HUVECs ranged from 5 to 10 kPa. Because the HL-60 cells are at least one order of magnitude softer than the HUVECs, the loading rate is mainly determined by the elasticity of the HL-60s during their separation from HUVEC.
Monocytes adhered more tightly to the cell border of a HUVEC monolayer. Past observations by Gopalan et al. (10) demonstrated that neutrophils preferentially adhered to the cell-cell junctions of a HUVEC monolayer. Hence, we decided to characterize the adhesive properties of PMA-differentiated HL-60 to the cell body of individual HUVEC and to the cell borders of the HUVEC monolayer by direct force measurements. Before the measurements, the HL-60 cells were carefully positioned above the cell bodies of individual HUVECs or above the cell-cell junctions formed by two adjacent HUVECs (Fig. 1B). During each force measurements, the contact zones between HL-60s and HUVECs were visualized using a light microscope equipped with a x40 objective to ensure that the cell-cell contacts occurred within HUVEC cell bodies or at cell-cell junctions.
Figure 6 plots the detachment force and work of deadhesion of HL-60 bound to either the cell body or cell border of a HUVEC monolayer. The AFM force measurement revealed that the adhesion depended on the site where the HL-60 makes contact with the endothelial cell monolayer. When HUVEC was activated by TNF-, the work of deadhesion was 105% higher at HUVEC cell borders compared with that of the cell bodies. However, in the resting HUVEC, the adhesion in cell bodies and borders only differed by 59%. Thus our measurements revealed that after activation, the enhancement of adhesion was more significant at the HUVEC cell borders.
|
Monocyte-HUVEC adhesion is partially inhibited by antibodies against P, E-selectins, ICAM-1, and VCAM-1. It has been previously reported that TNF- increases the expression level of E-selectin, ICAM-1, and VCAM-1 on vascular endothelial cells (3, 20). To more precisely define the relative contribution of these three molecules to leukocyte-HUVEC adhesion, the effect of function-blocking antibodies against these molecules was tested separately. Addition of antibody against P, E-selectins, ICAM-1, or VCAM-1 yielded a partial inhibition of the adhesion strength between HL-60 and TNF- activated HUVEC (Fig. 6). Regarding the work of deadhesion, anti-selectins and anti-ICAM-1 led to a significant inhibition of work of deadhesion in HUVEC cell boders but did not show significant blockade in the HUVEC cell bodies (Fig. 6B). In contrast, anti-VCAM-1 could inhibit HL-60 adhesion to both HUVEC cell bodies and cell borders significantly. Anti-VCAM-1 has the most potent inhibitory effect among these function-blocking antibodies, reducing 47% and 30% of adhesion strength in HUVEC cell borders and cell bodies, respectively. Surprisingly, a cocktail of all the four antibodies only resulted in a 65% and 55% blockade of adhesion strength in HUVEC cell borders and cell bodies, respectively, suggesting that 40% of adhesion strength could be contributed by molecules other than P, E-selectins, ICAM-1, and VCAM-1. A similar result was also found when adhesion strength is measured by detachment force (Fig. 6A). The adhesion between HL-60 and activated HUVECs was not affected by mouse Ig used as a negative control.
Monocyte adhesion is inhibited by a cRGD peptide. We have previously observed that a cRGD peptide exerted an inhibitory effect on leukocyte-endothelial cell adhesion (21). Together with the above demonstration of an only partial adhesion blockade achieved with all four neutralizing antibodies, we were prompted to investigate in depth the role of RGD peptides in leukocyte-endothelial interactions.
Addition of the cRGD peptide resulted in a dose-dependent decrease in work of deadhesion with an IC50 100 nM (Fig. 7A). The effects of cRGD peptide were independent of the site of adhesion to HUVEC. This effect was not observed with the cRAD peptide. The maximum blockade, performed by 10 µM of cRGD, led to a 60% reduction of adhesion strength in HUVEC borders and a 53% reduction in HUVEC bodies. This inhibitory potency is almost identical to that of the sum of function-blocking antibodies against P-, E-selectins, ICAM-1, and VCAM-1.
|
The known RGD recognizing integrins involved in leukocyte-endothelial interactions are the 1-integrins and V3 (28). In an attempt to identify the integrins involved in cRGD blockade, we tested two function-blocking monoclonal antibodies, i.e., JB1A (anti-1) and LM609 (anti-V3) for their ability to inhibit adhesion. Both JB1A and LM609 are well-characterized reagents and have been shown to block cell adhesion mediated by 1-integrins and V3, respectively (5, 11, 13, 18). Neutralizing antibody against the 1-integrin significantly suppressed HL-60-HUVEC interactions. However, neutralizing antibodies against the V3-integrin did not change HL-60 adhesion to HUVEC monolayers (Fig. 7B). The combined effect of anti-1 and cRGD was not significantly different from the inhibitory action of each individual compound (P < 0.05) (Fig. 7B), implying that the cRGD exerts this effect predominantly via the 1-integrins. It should be noted that inhibition of 1-integrins reduced adhesion by 60%, better than any other specific function-blocking antibodies tested. Hence, our data suggest that 1-integrins play an essential role in HL-60-HUVEC adhesion.
Because the cRGD seems to block the interaction of 1-integrins, we decided to test whether it inhibits VLA-4-VCAM-1 interaction. VLA-4 is one of the 1-integrins expressed in HL-60 cells (confirmed by FACS, data not shown). In the presence of 10 µM cRGD and the function-blocking monoclonal antibody to VCAM-1, we observed a 65% inhibition in work of deadhesion at HUVEC borders and a 52% inhibition at HUVEC bodies. This effect is very similar to that of cRGD alone (P > 0.05) (Fig. 7B), suggesting that cRGD did interfere with VLA-4-VCAM-1 interaction. However, the effect of cRGD is better than that of the VCAM-1 antibody alone, indicating that cRGD also has other targets. In another experiment, we added 10 µM cRGD and monoconal antibodies against P-, E-selectins, ICAM-1, and VCAM-1 (Fig 7B). In this experiment, work of deadhesion was further reduced to 75% and 65% in cell borders and bodies, respectively. Taken together, these results demonstrate that the action of cRGD is mediated through a blockade of VLA-4-VCAM-1 interaction and of some other 1-integrin interactions.
Using a standard adhesion assay, we were able to confirm the above findings. Adhesion of PMA-differentiated HL-60 cells to endothelial monolayers pretreated with TNF- was three to four times higher than to inactivated endothelial cells. Addition of cRGD peptide resulted in a dose-dependent inhibition of leukocyte adhesion with IC50 10 nM. In contrast, the cRAD peptide had no effect on HL-60-HUVEC adhesion (Fig. 7C).
Monocyte transmigration is inhibited by cRGD, anti-1, and anti-V3. Transmigration of HL-60 cells was studied using a modified Boyden chamber. In the presence of cRGD, HL-60 transmigration was reduced by 60%. Addition of neutralizing anti-V3 or anti-1 antibodies or their combination resulted in a partial but significant inhibition of transmigration, which was not significantly different from the inhibitory effect of cRGD peptide (P > 0.05) (Fig. 8). The peptide inhibited transmigration with the IC50 100 nM. cRAD peptide did not affect the transmigration of PMA-differentiated HL-60 (P > 0.05).
|
|
DISCUSSION |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
significantly enhances the adhesive strength at these sites, in accord with previous reports (10, 20). A cRGD peptide attenuates adhesion by interfering with VLA4-VCAM-1 interaction. An important difference between the AFM and other cell adhesion assays is that the AFM measures in real time the change of force and energy instead of counting the bound cell numbers afterward. Because the bound cell numbers do not reflect any biophysical properties, they can only be considered as a rough estimate of cell adhesion. The AFM method has overcome the previous technical difficulties in cell adhesion assays that prohibited examining the detailed dynamics of leukocyte-endothelial interaction. The spatial resolution of the AFM also allowed us to measure adhesion of a single leukocyte to different regions in an endothelial monolayer. Using the AFM approach, we have provided the first direct evidence of higher adhesive force developed in the HUVEC borders compared with the cell bodies. The mechanical work for separating a HL-60 cell from the cell borders of an activated HUVEC monolayer has been found to be twice as much as that of the HUVEC bodies. It has been shown that a vast majority of leukocyte transmigration occurred at the endothelial cell-cell junctions (28). Higher adhesive force at the endothelial cell borders may facilitate the accumulation of leukocytes into the proximity of endothelial cell junctions, thus favoring transendothelial migration. Certain factors could potentially account for this preferential distribution of adhesive forces: different expression levels of adhesion molecules, affinity or avidity activation of some adhesion molecules, and the geometry of the HUVEC monolayer. Past studies (1) using the AFM-imaging technique have revealed the surface contour of a bovine aortic endothelial monolayer. The boundaries between cells were visualized, and the average differential from the highest point of the cells (i.e., the nuclear region) to the lowest point at cell-cell junctions was averaging several microns. Hence, when a HL-60 cell was brought to interact with the junction formed by two HUVECc, it is conceivable that the round HL-60 cell (10–15 µm in diameter) could fit into the groove formed by adjacent HUVECs nicely. This would lead to an increase of the contact area between HL-60 and HUVECs and could potentially account for the enhanced adhesion in HUVEC borders. However, this hypothesis remains to be experimentally verified.
When cell adhesion on a surface presenting different adhesion molecules is measured, the AFM also provides an estimate of the relative contribution of each molecule in supporting whole cell adhesion. In the case illustrated in Fig. 3B, the adhesive system includes two adhesion molecules: VCAM-1 and P-selectin. Because the addition of function-blocking antibodies can completely eliminate adhesion, it can be estimated from the work of deadhesion that P-selectin and VCAM-1 contribute to 40% and 60% of total adhesion, respectively. In the case of HL-60-HUVEC interaction (Fig. 6), although the total adhesion was not completely blocked by a cocktail of all function-blocking antibodies, we could still roughly estimate the ratio of adhesion contributed by selectins, ICAM-1, and VCAM-1 as 1:2:2.5 in HUVEC borders and 1:4:6 in HUVEC bodies. Our data revealed that VCAM-1 supports monocyte adhesion to HUVEC better than ICAM-1 and selectins. This finding is consistent with a recent report suggesting a major role for VCAM-1 in the early stages of atherosclerosis (8).
Another major finding reported herein is an unexpected inhibitory effect of nanomolar concentrations of cRGD peptide on the adhesion of monocytic HL-60 to the activated endothelial cells and their transmigration across endothelial monolayer. The current paradigm on adhesive interactions engaged in these processes does not predict such an action; nonetheless, the observed effects of cRGD peptide (but not cRAD peptide) were so profound and confirmed using direct force measurements that they could not be ignored or ascribed to an artifact. The finding that effects of cRGD peptide could not be mimicked by the neutralizing anti-V3 antibody would indicate that this receptor is not directly involved in the initial leukocyte tethering and adhesion. In contrast, anti-1-integrin neutralizing antibody mimicked the effect of cRGD and their combined effect was nonadditive, suggesting that the cRGD peptide mediates its effect on monocyte-endothelial adhesion via 1-integrins. Consistently, the data revealed that cRGD peptide interfered with the VLA-4-VCAM-1 interaction. However, most likely this is not the only target that the cRGD inhibits. It is conceivable that the cRGD peptide exerts its action via a receptor(s) previously not known to recognize the RGD motif. Indeed, the recent finding that disintegrins affect leukocyte-endothelial interactions (25) provides additional support to the above observation.
Our data also show that HL-60 transmigration is inhibited by both anti-1 and anti-V3 antibodies. Therefore, it is not surprising that cRGD blocked HL-60 transmigration. Interestingly, no additional inhibition was found when 41 and v3 antibodies were added together. This may suggest that 41 and v3 are engaged sequentially during monocyte transmigration. It is also conceivable that the ligands of v3, such as L1 or PECAM, are localized within the endothelial cell-cell junctions (19, 26) and are not accessible to v3 during the initial adhesive contact. Our data suggest that v3 plays a significant role at a step after leukocyte firm adhesion to vascular endothelium.
In conclusion, we have developed a highly sensitive method to study the adhesive force in leukocyte-endothelial interaction. This technique is not limited to the chosen system and can potentially be used to study a broad range of cell-cell or cell-substrate interactions. The data demonstrate that the interaction of 1-integrins and their ligands play an important role in both leukocyte-endothelial adhesion and leukocyte transmigration. Both processes were substantially suppressed by a synthetic cRGD peptide. Our findings extend the previous usage of RGD peptides in blocking cell-to-matrix adhesion and raise the possibility of their therapeutic applicability in suppressing monocytic infiltration of the vascular wall, the necessary precursor in the formation of "fatty streaks."
|
ACKNOWLEDGMENTS |
|---|
These studies were supported in part by ACS and National Institutes of Health Grants GM-55611 (to V. T. Moy), DK-45462, DK-54602, and DK-45695 (to M. S. Goligorsky). X. Zhang was supported by a fellowship (0215139B) from the American Heart Association. H. Li was supported by the training grant from the National Institutes of Health T32DK-07521-14.
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|
REFERENCES |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. P. Gunning, S. Chambers, C. Pin, A. L. Man, V. J. Morris, and C. Nicoletti Mapping specific adhesive interactions on living human intestinal epithelial cells with atomic force microscopy FASEB J, July 1, 2008; 22(7): 2331 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Rhim and G. Tosato Targeting the Tumor Vasculature to Improve the Efficacy of Oncolytic Virus Therapy J Natl Cancer Inst, December 5, 2007; 99(23): 1739 - 1741. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Roca-Cusachs, I. Almendros, R. Sunyer, N. Gavara, R. Farre, and D. Navajas Rheology of Passive and Adhesion-Activated Neutrophils Probed by Atomic Force Microscopy Biophys. J., November 1, 2006; 91(9): 3508 - 3518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Subramanian, R. Parthasarathy, S. Sen, E. T. Boder, and D. E. Discher Species- and cell type-specific interactions between CD47 and human SIRP{alpha} Blood, March 15, 2006; 107(6): 2548 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Elitok, S. V. Brodsky, D. Patschan, T. Orlova, K. M. Lerea, P. Chander, and M. S. Goligorsky Cyclic arginine-glycine-aspartic acid peptide inhibits macrophage infiltration of the kidney and carotid artery lesions in apo-E-deficient mice Am J Physiol Renal Physiol, January 1, 2006; 290(1): F159 - F166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Litvinov, J. S. Bennett, J. W. Weisel, and H. Shuman Multi-Step Fibrinogen Binding to the Integrin {alpha}IIb{beta}3 Detected Using Force Spectroscopy Biophys. J., October 1, 2005; 89(4): 2824 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Goligorsky Whispers and shouts in the pathogenesis of acute renal ischaemia Nephrol. Dial. Transplant., February 1, 2005; 20(2): 261 - 266. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
